Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

327

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum Sensitive
BRCA Mutated
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy

Interventions

DRUG: Olaparib 300mg tablets
DRUG: Placebo to match olaparib 300mg

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]
[object Object]